Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Dermatology | Family Medicine

Clinical Trials: Malignant Melanoma


A listing of clinical trials currently looking for volunteers to enroll in Malignant Melanoma studies. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Arizona

Tucson :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

California

Beverly Hills : Call for Information (Investigational Site 0061) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Concord :

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Encinitas :

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

La Jolla : Moores UCSD Cancer Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

La Jolla :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

View More »

Los Angeles :

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Los Angeles :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Los Angeles :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Los Angeles :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Los Angeles :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Orange : Chao Family Comprehensive Cancer Center

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

San Diego : Rady Children's Hospital

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

San Francisco : St Mary's Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

San Francisco :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Santa Monica :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Santa Monica :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Colorado

Aurora :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Aurora :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Aurora :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Connecticut

New Haven : Yale University School Of Medicine

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Florida

Miami Beach : Mount Sinai Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Tampa :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tampa :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Illinois

Chicago : Rush University Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Chicago :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Niles : Oncology Specialists, SC

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Park Ridge :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Park Ridge :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Indiana

Goshen :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Indianapolis :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Iowa

Iowa City :

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Massachusetts

Boston :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Boston : Dana Farber Cancer Institute

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Michigan

Detroit :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Detroit :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Minnesota

Rochester :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Missouri

St Louis :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

St. Louis :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Nevada

Las Vegas :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

New Jersey

Morristown : Atlantic Melanoma Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Randolph :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

New York

New York :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

New York :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

New York : Memorial Sloan Kettering Cancer Center

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

New York :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

North Carolina

Charlotte :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Durham : Call for Information (Investigational Site 0036) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Oregon

Portland : Oregon Health and Science University

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Pennsylvania

Bethlehem :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Pittsburgh : University of Pittsburgh

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Pittsburgh :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Tennessee

Memphis : St. Jude Children's Research Hospital

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Memphis : St. Jude Children's Research Hospital

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Nashville :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Nashville :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Nashville : Call for Information (Investigational Site 0033) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

View More »

Nashville :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Texas

Dallas : Mary Crowley Cancer Research Centers

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Dallas :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Dallas : Mary Crowley Cancer Research Center

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Dallas :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Dallas : Mary Crowley Cancer Research Center

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

View More »

Houston :

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Houston : The Children's Cancer Hospital at UT M.D. Anderson Cancer Center

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Houston : University of Texas MD Anderson Cancer Center

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Utah

Salt Lake City : Huntsman Cancer Institute

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Washington

Seattle :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Albania

Tirana :

A Study of RO5185426 in Patients With Metastatic Melanoma

Australia

Ashford Sa :

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Melbourne :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Melbourne :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Wentworthville :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Belgium

Bruxelles :

A Study of RO5185426 in Patients With Metastatic Melanoma

Wilrijk :

A Study of RO5185426 in Patients With Metastatic Melanoma

Bosnia and Herzegovina

Banja Luka :

A Study of RO5185426 in Patients With Metastatic Melanoma

Sarajevo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Brazil

Rio de Janeiro - Rj :

A Study of RO5185426 in Patients With Metastatic Melanoma

Sao Paulo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Bulgaria

Plovdiv :

A Study of RO5185426 in Patients With Metastatic Melanoma

Sofia :

A Study of RO5185426 in Patients With Metastatic Melanoma

Canada

Edmonton :

A Study of RO5185426 in Patients With Metastatic Melanoma

Halifax :

A Study of RO5185426 in Patients With Metastatic Melanoma

Hamilton :

A Study of RO5185426 in Patients With Metastatic Melanoma

London :

A Study of RO5185426 in Patients With Metastatic Melanoma

Montreal :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Ottawa :

A Study of RO5185426 in Patients With Metastatic Melanoma

Quebec City :

A Study of RO5185426 in Patients With Metastatic Melanoma

Toronto :

A Study of RO5185426 in Patients With Metastatic Melanoma

Toronto :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Vancouver :

A Study of RO5185426 in Patients With Metastatic Melanoma

Winnipeg :

A Study of RO5185426 in Patients With Metastatic Melanoma

Winnipeg :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Colombia

Medellin :

A Study of RO5185426 in Patients With Metastatic Melanoma

Croatia

Zagreb :

A Study of RO5185426 in Patients With Metastatic Melanoma

Czech Republic

Brno :

A Study of RO5185426 in Patients With Metastatic Melanoma

Hradec Kralove :

A Study of RO5185426 in Patients With Metastatic Melanoma

Olomouc :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ostrava :

A Study of RO5185426 in Patients With Metastatic Melanoma

Praha :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ecuador

Guayaquil :

A Study of RO5185426 in Patients With Metastatic Melanoma

Portoviejo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Finland

Helsinki :

A Study of RO5185426 in Patients With Metastatic Melanoma

France

Bordeaux :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Lille :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nice :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Paris :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Germany

Essen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Frankfurt :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Freiburg : University Medical Center Freiburg, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Jena :

A Study of RO5185426 in Patients With Metastatic Melanoma

Kiel :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

View More »

Köln : University Medical Center Collogne, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Mannheim :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Münster :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tübingen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Wiesbaden :

A Study of RO5185426 in Patients With Metastatic Melanoma

Greece

Athens :

A Study of RO5185426 in Patients With Metastatic Melanoma

Heraklion :

A Study of RO5185426 in Patients With Metastatic Melanoma

India

Hyderabad :

A Study of RO5185426 in Patients With Metastatic Melanoma

Lucknow :

A Study of RO5185426 in Patients With Metastatic Melanoma

Nashik :

A Study of RO5185426 in Patients With Metastatic Melanoma

New Delhi :

A Study of RO5185426 in Patients With Metastatic Melanoma

Trivandrum :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Vellore :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ireland

Cork :

A Study of RO5185426 in Patients With Metastatic Melanoma

Dublin :

A Study of RO5185426 in Patients With Metastatic Melanoma

Galway :

A Study of RO5185426 in Patients With Metastatic Melanoma

Limerick :

A Study of RO5185426 in Patients With Metastatic Melanoma

Waterford :

A Study of RO5185426 in Patients With Metastatic Melanoma

Israel

Hod Hasharon : Merck Sharp & Dohme Co. Ltd. Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Jerusalem : Oncology institute, Shaare Zedek Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel Hashomer : Oncology Institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel-hashomer :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Italy

Bari :

A Study of RO5185426 in Patients With Metastatic Melanoma

Bergamo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Brescia :

A Study of RO5185426 in Patients With Metastatic Melanoma

Firenze :

A Study of RO5185426 in Patients With Metastatic Melanoma

Genova :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Meldola :

A Study of RO5185426 in Patients With Metastatic Melanoma

Milano :

A Study of RO5185426 in Patients With Metastatic Melanoma

Napoli :

A Study of RO5185426 in Patients With Metastatic Melanoma

Padova :

A Study of RO5185426 in Patients With Metastatic Melanoma

Pisa :

A Study of RO5185426 in Patients With Metastatic Melanoma

Roma :

A Study of RO5185426 in Patients With Metastatic Melanoma

Siena :

A Study of RO5185426 in Patients With Metastatic Melanoma

Siena :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Udine :

A Study of RO5185426 in Patients With Metastatic Melanoma

Korea, Republic of

Seoul :

A Study of RO5185426 in Patients With Metastatic Melanoma

Lithuania

Klaipeda :

A Study of RO5185426 in Patients With Metastatic Melanoma

Vilnius :

A Study of RO5185426 in Patients With Metastatic Melanoma

Macedonia, The Former Yugoslav Republic of

Skopje :

A Study of RO5185426 in Patients With Metastatic Melanoma

Mexico

Leon :

A Study of RO5185426 in Patients With Metastatic Melanoma

Mexico City :

A Study of RO5185426 in Patients With Metastatic Melanoma

Netherlands

Amsterdam :

A Study of RO5185426 in Patients With Metastatic Melanoma

Amsterdam :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Blaricum :

A Study of RO5185426 in Patients With Metastatic Melanoma

Breda :

A Study of RO5185426 in Patients With Metastatic Melanoma

Groningen :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Groningen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Maastricht :

A Study of RO5185426 in Patients With Metastatic Melanoma

Norway

Bergen :

A Study of RO5185426 in Patients With Metastatic Melanoma

Drammen : MSD (Norge) AS Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Oslo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Peru

Arequipa :

A Study of RO5185426 in Patients With Metastatic Melanoma

Lima :

A Study of RO5185426 in Patients With Metastatic Melanoma

Portugal

Porto :

A Study of RO5185426 in Patients With Metastatic Melanoma

Romania

Timisoara :

A Study of RO5185426 in Patients With Metastatic Melanoma

Serbia

Belgrade :

A Study of RO5185426 in Patients With Metastatic Melanoma

Slovenia

Ljubljana :

A Study of RO5185426 in Patients With Metastatic Melanoma

South Africa

Bloemfontein :

A Study of RO5185426 in Patients With Metastatic Melanoma

Cape Town :

A Study of RO5185426 in Patients With Metastatic Melanoma

Johannesburg :

A Study of RO5185426 in Patients With Metastatic Melanoma

Pretoria :

A Study of RO5185426 in Patients With Metastatic Melanoma

Spain

Barcelona :

A Study of RO5185426 in Patients With Metastatic Melanoma

Barcelona :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Cartagena (murcia) :

A Study of RO5185426 in Patients With Metastatic Melanoma

Cordoba :

A Study of RO5185426 in Patients With Metastatic Melanoma

Granada :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

La Coruna :

A Study of RO5185426 in Patients With Metastatic Melanoma

La Laguna (tenerife) :

A Study of RO5185426 in Patients With Metastatic Melanoma

Las Palmas de Gran Canaria :

A Study of RO5185426 in Patients With Metastatic Melanoma

Leon :

A Study of RO5185426 in Patients With Metastatic Melanoma

Madrid :

A Study of RO5185426 in Patients With Metastatic Melanoma

Madrid :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Malaga :

A Study of RO5185426 in Patients With Metastatic Melanoma

Málaga :

A Study of RO5185426 in Patients With Metastatic Melanoma

Palma de Mallorca :

A Study of RO5185426 in Patients With Metastatic Melanoma

Pamplona :

A Study of RO5185426 in Patients With Metastatic Melanoma

Pamplona :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Salamanca :

A Study of RO5185426 in Patients With Metastatic Melanoma

Santander :

A Study of RO5185426 in Patients With Metastatic Melanoma

Sevilla :

A Study of RO5185426 in Patients With Metastatic Melanoma

Valencia :

A Study of RO5185426 in Patients With Metastatic Melanoma

Vigo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Zaragoza :

A Study of RO5185426 in Patients With Metastatic Melanoma

Sweden

Lund : Lunds Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Stockholm : Södersjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Stockholm : Karolinska Sjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Umeå : Norrlands Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Turkey

Adana :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ankara :

A Study of RO5185426 in Patients With Metastatic Melanoma

Antalya :

A Study of RO5185426 in Patients With Metastatic Melanoma

Gaziantep :

A Study of RO5185426 in Patients With Metastatic Melanoma

Istanbul :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Izmir :

A Study of RO5185426 in Patients With Metastatic Melanoma

United Kingdom

Birmingham : Queen Elizabeth Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Cambridge :

A Study of RO5185426 in Patients With Metastatic Melanoma

Cambridge : Addenbrooke's Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Glasgow :

A Study of RO5185426 in Patients With Metastatic Melanoma

Glasgow : The Beatson Institute

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

View More »

Leeds :

A Study of RO5185426 in Patients With Metastatic Melanoma

Leeds : St James' Institute of Oncology

Study of a DNA Immunotherapy to Treat Melanoma

Leeds : St James Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

London :

A Study of RO5185426 in Patients With Metastatic Melanoma

Manchester :

A Study of RO5185426 in Patients With Metastatic Melanoma

Manchester : Christie Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Newcastle Upon Tyne :

A Study of RO5185426 in Patients With Metastatic Melanoma

Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Northwood :

A Study of RO5185426 in Patients With Metastatic Melanoma

Northwood :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nottingham :

A Study of RO5185426 in Patients With Metastatic Melanoma

Nottingham : Department of Clinical Oncology, City Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Oxford :

A Study of RO5185426 in Patients With Metastatic Melanoma

Oxford : NIHR Biomedical Research Centre

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Southampton :

A Study of RO5185426 in Patients With Metastatic Melanoma

Southampton : Department of Medical Oncology, Southampton General Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Swansea :

A Study of RO5185426 in Patients With Metastatic Melanoma